Endexx Launches New and Improved Formula for its Best Selling Phyto-Bites Product
Company announced its best-selling CBD-infused soft chews for dogs and cats now contain premium high quality ingredients without the sugar
CAVE CREEK, AZ, May 02, 2018 (GLOBE NEWSWIRE) — Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, is pleased to announce the launch of its new and improved formula for top selling product Phyto-Bites®, its CBD-infused soft chews for cats and dogs, formulated to promote health and support the reduction of separation Calming, Soothing and Relaxing.
Endexx has created a new advanced formula, as a result of veterinarian and customer feedback from the past year. The Company has now added coconut oil and sweet potato to the mix and removed all sugar from its ingredients.
The new Phyto-Bites ® also include large and small dog dosing and now dosing for cats too. The customer and vet feedback suggest that Phyto-Bites ® works in real time applications immediately reducing nervousness, shaking, stress and Soothing when precisely administered.
Todd Davis, Chief Executive Officer of Endexx said, “We’ve received an overwhelming amount of positive reviews for our best-selling product and now we’ve added high quality ingredients with a more powerful formulated concentration to enhance the benefits of our product. In addition, we have made this available to both our feline and canine friends.” Mr. Davis added, “Phyto-Bites ® has now proved to be a product that immediately impacts and improves the quality of life for pets and people. When you see an animal change from miserable to happy in front of your eyes, one thing is for certain, dogs don’t lie.”
Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites® is its CBD-infused soft chews for dogs and cats. The dog treats are formulated to promote health and support the reduction of separation Calming, Soothing and Relaxing. The company also has two technology products and services that launched in 2014 – the m3hub and the AutoSpense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and an “end of sale” technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical-grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The AutoSpense™ is a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, AutoSpense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include www.cbdunlimited.com, www.endexx.com and www.phytobites.com.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
For further investor and media information, contact: Endexx Corporation Todd Davis Chairman & CEO [email protected] 480-595-6900
Endexx Announces Global CBD License & Distribution Deal With Hemp Infusion Brand The Mad Hatter Coffee & Tea Co.
Endexx Initiates Adaptive Clinical Study With Proprietary CBD Capsule Formulation To Address Neuropathic Soothing